Biologically active food additive based on honey and antler deer farming products

FIELD: food industry.

SUBSTANCE: biologically active food additive contains dry blood of antler deer, an antler concentrate and honey at the following components ratio, wt %. antler concentrate - 8-10; dry blood - 2-3; honey - 87-90.

EFFECT: invention allows to produce an additive having the optimal ratio of components and having high adaptogenic and tonic properties.

4 tbl, 1 ex


The invention relates to food industry, in particular for food additives, enriched with natural biologically active substances.

Known biologically active product on the basis of fine or ultra-fine powder of canned antlers or canned side of raw and natural honey. The product is obtained by extraction antler raw honey in a water bath at a ratio of raw material:solvent 1:10 or 1:20. The drug has anti-stress, toning, radioprotective and biostimulating effect (patent RF №2345573, IPC A23L 1/30, A23L 1/08, A61K 35/28, A61K 35/32).

Known biologically active product of the antlers and blood used to prepare the antler decoction bath, wet wraps, microenemas, compresses, inhalations (RF patent No. 2268058, IPC A61K 35/32, A61K 35/14).

Known means on the basis of nedifferentsirovannoi deer blood, deer or spotted deer taken during the period from June to November and dried to a moisture content of 4-5%. The tool has nootropic and adaptogenic action (patent RF №2130314, IPC A61K 35/14).

However, extraction of powders antler or in the preparation of decoctions from antlers, a very small portion of biologically active substances, and the use of only dry blood biochemical and biological properties of the final products is that are less saturated spectrum of biologically active components.

Known biologically active food Supplement, containing, mass%: stable blood reindeer, deer and Yakut horses - 55, antler product in the form of alcoholic extract of antlers (70% solution of ethyl alcohol) - 10, 30% solution floral honey - 35, and represents a syrupy liquid brownish-red (patent RF №2368250, IPC A23L 1/30, A61K 35/14, A61K 35/32, A23L 1/08, A23L 1/302 - prototype).

However, the use of alcoholic extract of intolerance user of alcohol, as well as the ingestion brownish-red liquid resembling blood, psychologically limits the user base. In addition, when alcohol extraction antlers in the extract goes only about 3% of dry substances panta, which implies inefficient use of antler raw materials, and stabilization of blood brings in the composition of the biologically active product is not useful chemicals. All this ultimately reduces consumer properties of the product.

Task to be solved by the claimed invention is directed, is the expansion of the range of biologically active products using raw materials from deer antler with high consumer properties, with the optimum combination of components that determine the rational use of raw materials at high biologicallyactive.

This object is achieved in that the biologically active additive containing honey, the blood of deer antler and the antler product, according to the claimed invention, as antler product use concentrate on THE 9860-010-29734071-11, and the blood is introduced into a dry form in the following ratio, wt.%:

Dry blood2-3

The essence of the claimed invention is found that the optimum ratio of components of the additive, with the additive in appearance and taste similar to natural honey, when the use does not cause psychological stress to the user and highly adaptogenic and tonic properties.

Honey as a food product contains invert sugar (65-80%), sucrose (8%), dextrin (polysaccharides) (1-5%), organic acids (malic, citric, oxalic, lactic and other) (0,01-0,4%), macro - and microelements (0,01-0,4%), enzyme - diastasis, invertase, catalase, vitamin B1B2, PP, C, Pantothenic and nicotinic acids, alkaloids (Veterinary encyclopedia. - So 3, 172 - S. 1062).

Due to its biochemical composition, honey is widely used in medicine, cosmetics, food industry, perfumery, increasing metabolic and immunological processes, exerting a positive influence on the prevention and treatment of many diseases, providing a living organism with energy and restore tissue trophism (agricultural science - agriculture / IV international scientific-practical conference. - Barnaul: Publishing house of agau, 2009. - KN.3. - S. 250-252).

Concentrate (TU 9860-010-29734071-11, RF patent №2461384) it has high biological activity due to the presence not only of the high content of amino acids, vitamins, macro - and micronutrients and hormones, but mostly because of the content of growth factors, possessing a wide spectrum of biological effects, namely, stimulating or inhibiting mitogenes, chemotaxis and differentiation (maturation) of the cells of the body. Thus, insulin-like (IGF) and epidermal (EGF) growth factors promote cell division and maturation of cells occurs under the action of alpha - and beta-transforming growth factor (TGF). In addition, transforming growth factor involved in cell proliferation and regulation of the growth of tumor cells, nerve growth factor (NGF) stimulates the regeneration of damaged neuro structures organism.

Growth factors push "p is anew old" cells, i.e. have a rejuvenating effect on the tissues and the whole body: re-run ofine old age or disease genes, directed stimulate metabolism in cells, have a positive effect on the prevention of hyperplastic processes (breast, uterine fibroids, endometriosis). The effect of growth factors should be considered in connection with other stimulants, especially with hormones, for example, dehydroepiandrosterone (DHEA), which is also part of the antler concentrate.

Dehydroepiandrosterone (DHEA) - the "mother hormone" of the body, is the basis on which the endocrine glands produce 27 of hormones, including testosterone and dihydrotestosterone. The increase of DHEA in the body can not only slow the aging process, but also to improve the condition of patients with cancer, memory loss, osteoporosis, heart diseases and so on

However, studies have found that the greatest amount of this hormone is found in dry blood antler deer. Content in dry blood DHEA exceeds its concentration in antler concentrate 30 times. In addition, dry blood slightly, but surpasses concentrate on insulin-like (IGF) and transforming (TGF) growth factors, as well as on the content of interleukin 2 and 6. Thus, according to some authors, 1 liter of blood can give will complement the flax 64% more biologically active substances (GED), than that obtained from the standard 2-Kontsevich one deer antlers (Antlers and antler: horns as a medicinal raw materials / A. M. Yudin. - Novosibirsk: Nauka, Siberian publishing company, 1993. - S. 83-87).

Blood and antlers equally improve the information the brain, the immune system, slow the aging process, have a positive impact on sexual function and so on (Antler drugs priority in innovation in reindeer antler) / N. A. Frolov, V., Loniten. - Barnaul: Publishing house of Alt. University, 2007. - S. 29-32).

Thus, the blood antler deer can be widely used for manufacturing a prophylactic and therapeutic action as a cheaper (the cost of dry blood more than 2 times lower antler concentrate and affordable product.

However, despite the high biological activity, the products of reindeer antlers, in particular concentrate, is almost never used in medical practice, and dry blood in drugs or food products contained in concentrations that do not provide adequate effect.

Studies to determine the optimal percentage of the introduction of honey antler concentrate is presented in table 1. Biological properties of honey and honey with the addition of antler concentrate was determined by adaptogenic and tonic is the effect on white mice. Honey and honey with additives was pre-dissolved in physiological solution at a ratio of 1:5 (honey:water) and the probe was introduced into the stomach 0.15 ml/mouse, within 14 days.

As can be seen from table 1, the optimum content of the antler concentrate in honey varies in the range of 8-10%. For a given concentration of antler concentrate honey adaptogenic and tonic effect of the product was superior to the control (honey with no additives), respectively, in 1,79-of 1.85 and 2.10-2.17 times.

Table 1
Determination of the optimum percentage of antler concentrate and honey
IndexThe content in honey antler concentrate, %Control (100% honey with no additives)
Adaptogenic action143,6±14,2EUR 188.4±13,8194,5±14,7195,1±15,2of 105.2±13,6
Tonic effectof 124.6±5,516,3±6,1 160,6±6,5161,2±6,974,4±5,9

It should be noted that a further increase in the number of antler concentrate product did not provide a significant increase biological properties.

In further conducted studies to determine the optimal content of dry blood maral in honey with antler concentrate (8-10%) by analogy with the first experience.

Table 2
Determination of the optimum percentage of dry blood in honey with antler concentrate (9,0%)
IndexThe content of dry blood in honey with antler concentrate, %Control (honey content antler concentrate 9,0%)
Adaptogenic action201,7±15,2238,4±15,4246,5±15,7to 244.1±15,2190,2±16,6
Tonic effect 189,6±7,5233,7±8,1238,6±8,5239,3±7,9164,4±6,5

The studies (table 2) found that the addition of dry blood red to honey containing concentrate, improved biological properties of the product. So, when 1% of dry blood adaptogenic and tonic properties of biologically active additives (product) increased 6.0 and 15.3%, respectively. If 2-3% of dry blood biological properties increased by 29.6 and 45.1%, and observed a similar trend with previous experience with increasing concentration of dry blood (more than 3,0%) biological properties of food additives was not significantly increased.

Comparative effects of products made on the prototype, honey, honey, enriched antler concentrate (9%) and dry blood red deer (2%), biological parameters of laboratory animals is presented in table 3. In addition adaptogenic and tonic actions studied the health of laboratory animals in tests - open field, "Shuttle run", "stairs", "hot plate". The feeding of the analyzed products is carried out by analogy first experience.

Tab the Itza 3
The determination of the biological properties of honey antler concentrate and dry blood, honey with no additives or product prototype
The test nameHoney with antler concentrate and dry blood (n=12)Honey (n=12)Prototype (n=10)
Adaptogenic effect, min251,2±10,6110,6±8,2167,8±10,2
A tonic effect, min237,4±8,983,3±7,4of 153.6±8,7
Open field (the number of runs for 5 minutes)43,5±3,521,6±2,2of 31.8±2,1
"Shuttle run" (run rate for 5 minutes)37,6±2,915,9±2,121,7±1,9
"The ladder" (number of steps per 5 minutes)29,4±1,612,5±1,319,4±1,4
"Hot plate",40,5±1,4 10,3±1,328,6±3,9

The studies found high biological indicators developed biologically active additives (honey antler concentrate and dry blood) compared with honey and prototype (table 3).

Conducted studies on acute and chronic toxicity declared biologically active food supplements showed no mortality and changes in their internal organs, which indicates the safety of the resulting product.

Example. The product is prepared as follows: to 900,0 g honey add 85,0 g antler concentrate and 25.0 g of dry blood, after which the ingredients are mixed in a mixer at low speed (about 50-100 rpm), after mixing, the product is Packed in consumer packages.

Table 4
Organoleptic characteristics of the product
Name of indicatorIndex
ColorFrom straw-yellow to brown with a reddish tint
SmellThe smell of honey
Taste Sweet, pleasant, characteristic of honey with a taste of antlers
ConsistencyTypical honey

Thus, a biologically active additive to food on the basis of honey that contains the optimal ratio of products of reindeer antlers (concentrate and dry blood maral), in appearance and taste close to the natural honey, when the use does not cause psychological stress to the user and highly adaptogenic and tonic properties, i.e., increasing consumer properties.

Biologically active food Supplement based on honey and products of reindeer antlers containing blood antler deer antler product and honey, characterized in that as the antler product use concentrate, and the blood is introduced into a dry form in the following ratio, wt.%:
Concentrate - 8-10
Dry blood - 2-3
Honey - 87-90.


Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions deals with medical prostheses for implantation into a human organism and methods of their manufacturing, in particular prosthesis of the jaw bone, which can be used in cosmetic surgery of the jaw bone or in the jaw bone reconstruction. Claimed is an implant of the jaw bone, manufactured in accordance with the method, including the following stages: selection of material of animal origin from an organism of cattle or pigs, with the material of animal origin being the jaw bone; shaping the material of animal origin to obtain a desirable shape of the jaw bone implant; removal of cells from the material of animal origin, crosslinking of the material of animal origin; removal of antigens from the material of animal origin; subjection of the material of animal origin to alkaline processing; introduction of active substances, improving adhesion on the implant of the growth factor and stem cells, produced by the human organism into the material of animal origin; packing the material of animal origin into a container with a sterilising solution. The jaw bone implant, manufactured by the said method, possesses high tissue compatibility.

EFFECT: group of inventions provides elimination of development or, at last, minimisation of phenomena of various types of discomfort under an impact of moving muscles in the period of the implant growing into tissues of the host organism, resorption and replacement with the new bone tissue with simultaneous provision of high tissue compatibility with elimination, or, at least, minimisation of phenomena of immunological rejection of a biological prosthesis of the jaw bone.

14 cl, 1 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: what is described is a combined bone allograft representing a non-demineralised bone block prepared of a donor's spongy bone and containing human type I collagen in the form of a fine-cellular sponge prepared by lyophilisation of the bone block impregnated with a collagen solution, throughout the bone block. What is described is a method for preparing the combined bone allograft providing preparing the non-demineralised bone block of the donor's spongy bone, impregnating the bone block with the human type I collagen solution and conducting lyophilisation under the conditions providing the collagen solution transformation into the fine-cellular sponge throughout the bone block.

EFFECT: biocompatible combined bone allograft possesses the mechanical strength, osteoconductive effect, and stimulates osteogenesis.

12 cl

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to dentistry, and may be used for making a restoration material used for partial dental restoration in the oral cavity. That is ensured by placing the first cell mass formed by mesenchymal or epithelial cells/cell and a second cell mass formed by other mesenchymal or epithelial cells/cell on a carrier. One of the mesenchymal or epithelial cells is made from a dental germ, and the above cell masses are placed in tight contact to each other, but not mixed. The above cell masses are grown to form the whole restored tooth or its germ. That is followed by localising the whole restored tooth or its germ grown that enables implanting the whole restored tooth or is germ within the lost tooth so that a dental crown is directed inside the oral cavity with the dental germ or the tooth being used as the restoration material for preparing an equivalent of the lost tooth within the lost tooth area.

EFFECT: group of inventions enables performing partial dental restoration within the lost tooth area by implanting the restored dental germ or the whole restored tooth, as prepared by the above method.

10 cl, 5 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to an agent for treating benign prostatic hyperplasia. The antiproliferative agent for treating benign prostatic hyperplasia which contains red deer's antler lipids prepared by extraction of the red deer's antlers in a mixture of the solvents ethanol: ethyl acetate: water in the specific environment.

EFFECT: agent is effective for treating benign prostatic hyperplasia.

2 tbl

FIELD: chemistry, pharmacology.

SUBSTANCE: biologically active composition for improving sexual function in men includes powder of antlers of Maral, or Manchurian wapiti, or sika deer, and additionally contains powder of leaves or rhizomes with roots of Rhaponticum carthamoides, taken in specified ratio (version).

EFFECT: composition makes it possible to extend spectrum of highly efficient preparations for improvement of sexual function in men with minimal quantitative content of highly effective components from plant and animal raw material, demonstrating action synergism as components of composition.

4 cl, 6 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: method for prevention of dental caries with using a suspension of the biologically active additive 'Epsorine' involves applications of the suspension either daily, or every second day; the daily procedures contain min 4 applications of the total treatment time up to 20 minutes; the prevention course makes 10 procedures. Besides, the prevention course is repeated 2-3 times a year every 3-4 months for the main indication.

EFFECT: higher caries stability of dental tissue.

3 tbl

FIELD: medicine.

SUBSTANCE: what is described is a method for preparing a bone mineral component consisting in the fact that a bone spongy tissue is sawn up to bricks of 0.008 to 0.125 cm3, that are immersed into 2% sodium chloride that is followed by salting out of proteins, blood corpuscles and fat particles from bone spongy tissue trabecular for 24÷48 hours; the bricks are flushed with water; hydrolysis is performed in 2% sodium hydroxide for 24÷48 hours; the hydrolyzate is poured out, while the bricks are flushed with water while stirring continuously to neutralise sodium hydroxide completely; the bricks are immersed into 3-4% hydrogen peroxide for 10÷16 hours; the bricks are flushed with water; the bricks are degreased for 48 to 72 hours in mixed chloroform and ethanol taken in 2:1; the bricks are flushed in distilled water while stirring continuously, then heated, increasing temperature from 600 to 1200°C gradually, and additionally heated to 1200÷1300°C for 2-5 minutes.

EFFECT: preparing the bone mineral component with the manifested osteoconductive effect.

6 cl, 2 ex

FIELD: medicine.

SUBSTANCE: what is described is an osteoplastic composition containing a mixture of hyaluronic acid, chondroitin sulphate and heparin in sodium chloride and an osteoconductive material presented by non-demineralised osseine or demineralised osseine in the following ratio of the ingredients, wt %: hyaluronic acid 0.1-4.0, chondroitin sulphate 0.1-4.0, heparin 0.1-0.5, non-demineralised osseine or demineralised osseine 25-94.0, sodium chloride 0.8-0.85, distilled water - the rest. According to the other version, the osteoplastic composition uses an osseous mineral ingredient as an osteoconductive material.

EFFECT: osteoplastic composition is presented in the form of gel or chips, and possesses the protective viscoelastic properties prolonging the osteoconductive and osteoinductive properties of the ingredients of the composition filling and keeping the bone defect volume by the fact that they are considered as the natural mechanical support components of the bone tissue.

4 cl, 3 dwg, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and particularly to preparations for a therapy of oncological diseases, treatment of allergy, prevention and health improvement. The invention represents a method for preparing fraction 4 (ADP-f4) and fraction (ADP-f5) adaptogenic Dorogov's preparations, characterised by the fact that a primary product is a fraction 2 antiseptic Dorogov's stimulator (ADP-f2) to be thermally treated.

EFFECT: implementing the given invention provides the more effective prevention and eliciting anti-stress reactions for the purpose of improving the functional state of organism and increasing a resistance in an activation therapy.

2 tbl

FIELD: medicine.

SUBSTANCE: present invention refers to medicine and concerns a method for pulp cell culture without the impairment of a live pulp cell function, and a method for extracted tooth placement in storage. The method for pulp cell sampling involving straight marking of the extracted tooth surface, extracted tooth splitting along the mark and pulp exposure followed by extracted tooth soaking in a fluid and soaked tooth placement with maintaining the temperature suitable for cell storage.

EFFECT: invention provides extracted tooth placement for pulp cell culture and preservation.

6 cl, 1 ex, 5 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: group of inventions relates to field of veterinary. Claimed method includes obtaining antiplacental blood (APB) from young healthy horse 14 days after subcutaneous double introduction of placentolysate of cows, which contains parts of cotyledons and caruncles, with 14-day interval in dose 20 ml, and method of treatment and prevention of afterbirth retention, uterus subinvolution and postnatal endometritis in cows by application of antiplacental blood (APB), stimulating postnatal involution of genitals of newly calved cows, which is introduced subcutaneously in the area of neck two times in dose 10 ml, with 6 day interval.

EFFECT: application of antiplacental blood (APB) reduces duration of postnatal involution of genitals, which makes it possible to prevent and reduce terms of treatment of ill cows in case of afterbirth retention, uterus subinvolution and postnatal endometritis.

2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a biologically active food supplement. The biologically active food supplement possessing the adaptogenic and tonic action and containing antler reindeer's whole blood, antler concentrate according to Technical Specifications (TU) 9860-010-29734071-11, honey, fruit essence, ascorbic acid and Citrosept Grapefruit taken in certain proportions.

EFFECT: formulation enables preparing the biologically active food supplement possessing the enhanced adaptogenic and tonic action.

2 cl, 8 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: composition 16-21ml consisting of a mixture of therapeutic preparations: Dona glucosamine sulphate 3.0 ml; ChondroGuard, or Mucosatum, or Chondrolon chondroitin sulphate - 2.0 ml; Alflutop 2.0 ml; Actovegin 4.0-5.0 ml; glucocorticosteroids Depo-Medrol 1.0-2.0 ml in the concentration of 40 mg/ml, or Diprospane 1.0-2.0 ml in the concentration of 7 mg/ml, or Metipred 1.0-2.0 ml in the concentration of 62.5 mg/ml; vitamins B1, B6, B12 Combilipen 2.0 ml, or Milgamma 2.0 ml, or Neurobion 3.0 ml; 95% or 70% ethanol 2.0-4.0 ml, is administered into a pathologically changed region. That is immediately followed by exposing the pathologically changed region and adjoining segments to a session of A shock-wave therapy in the following mode: pressure 1.2 - 4.0 bar, frequency 7-12 Hz, beat quantity 8000-14000 for 20-40 minutes. The complex procedures are performed within the course of 1-6 times every 7-10 days.

EFFECT: method enables the direct exposure on the pathologically changed region to achieve the optimum concentration of drug preparations therein with avoiding systemic prescription and preventing a risk of side effects.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to a method of pantohematogen production. The method of the pantohematogen production includes sampling blood six times from June to November from culled stags, blood freezing; in the process of production the defrosted blood is homogenised and mixed with sugar syrup, fruit essence and ascorbic acid, the mixture is pasteurised and a preservative "Citrosept grapefruit" is introduced under certain conditions.

EFFECT: method possesses the expressed general toning and stimulating action.

4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a topical pharmaceutical preparation for treating inflammatory skin pathologies, preferentially an ischemia-related skin pathology. The above preparation contains a supernatant of normal saline prepared by culturing for at least 1 hour peripheral blood mononuclear cells (PBMC) or their subpopulation in normal saline free from substances promoting the PBMC proliferation and activating the PBMC in the stress-inducing environment. Also, the invention refers to a method for producing and using the above preparation.

EFFECT: invention promotes relieving the symptoms of the inflammatory skin pathologies and the healing process.

20 cl, 18 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: method for preparing a haematogenous powder from a blood clot involves blood sampling from animals or humans, setting-out and centrifugation of the blood with forming of blood serum and blood clot; the blood serum is poured off, and the blood clot is poured into a vessel and added with ethanol and incubated; the blood clot is then separated, dried and powdered under certain conditions.

EFFECT: method enables preparing the haematogenous powder from the blood clot containing all primary blood components.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and aims at conservative treatment of plantar fasciitis. That is ensured by administering platelet rich autoplasma in an amount of 2.0 ml for each injection into an attachment point of the plantar aponeurosis to the calcaneum (the heel sac), inner and outer side surfaces of a midfoot, as well as to a plantar surface of the midfoot. The autoplasma is prepared 1-2 hours before the procedure, and it contains from 1243 thousand/mcl to 3029 thousand/mcl platelets. The normal autoplasma contains from 162 thousand/mcl to 358 thousand/mcl platelets. The autoplasma is activated with 0.25% CaCl2 in a ratio of 2:1 with added 5% sodium hydrocarbonate in a ratio of 1:20 to the prepared platelet rich plasma.

EFFECT: above method enables providing pain management, recovering the extremity function, ensuring the stable clinical effect, and preventing complications.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery, and can be used in treating patients with pancreatonecrosis. For this purpose, opening the omental sac and performing the pancreatic gland abdomination along a lower edge of its body and tail are followed by puncturing retroperitoneal fat with introducing components No.1 and No.2 therein. First, component No.1 consisting of dry lyophilized cryoprecipitate 50-70 g dissolved in normal saline 100 ml is slowly administered. Then 10 minutes later, the retroperitoneal fat is additionally punctured, and component No.2 consisting of NIH sterile thrombin dissolved in 5% s-aminocapronic acid 10 ml is introduced. An artificial fibrin barrier is formed in the retroperitoneal fat 5-7 minutes later by mixing and polymerising the two solutions.

EFFECT: method provides the effective treatment of pancreatonecrosis by forming the artificial fibrin barrier on the way of a potential impregnation of the retroperitoneal fat in an enzymatic fluid.

3 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be applied for antitumour immunotherapy. For this purpose, dendritic cells (DC), obtained from a patient's skin, spleen, bone marrow, thymus, lymph nodes, umbilical blood or peripheral blood (autologous DC) are introduced to the patient, with DC being introduced to the patient step-by-step. At the first stage the introduction of mature allogenic DC, loaded with a tumourspecific antigen, maturation of which is realised ex vivo, is performed. At the second stage not less than 24 hours, but not more than 120 hours after the first stage the re-introduction of allogenc DC is realised simultaneously with the introduction of immature autologous DC in situ in a tumour, with the tumour being subjected to an ablation impact preliminarily or simultaneously with DC introduction.

EFFECT: application of the claimed method makes it possible to achieve an increased immune response by the introduction of a two-component immune agent, which consists of a sensitising dose of allogenous mature cells and a therapeutic dose of immature DC, with 10% of the therapeutic DC dose being sufficient for sensitisation.

2 cl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a biological material containing: a) a liquid carrier containing a viscous solution containing at least one natural and/or semisynthetic polysaccharide and having a dynamic viscosity measured at 20°C and at shear rate D=350 s-1, within the range of 100 to 250 centipoise and/or kinematic viscosity within the range of 99 to 248 centistokes (measured in the same environment); b) a autologous or heterologous mesenchymal cell culture and/or c) platelet rich blood product.

EFFECT: material in form of viscous liquid is particularly applicable for the therapy of osteoarthritis, ligament injuries and administered intra-articularly, intradermally or applied in situ without change of the properties of the mesenchymal stem cells and/or its platelets.

11 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a composition containing copepods fat, and to using this composition for reducing a visceral fat storage. The composition of copepods fat contains wax esters 20-100 wt %, preferentially wax esters 40-85 wt %. The above wax esters consist of monoesters, preferentially mono- or polyunsaturated C16-C22 fatty acids and preferentially monounsaturated C16-C22 fatty alcohols. What is also presented is a preparation containing the above composition.

EFFECT: invention enables preparing the composition used as a drug for preventing or treating abdominal obesity and diabetes mellitus type 2.

22 cl, 3 dwg, 3 tbl